AZTEC trial

Chief investigator - Dr Ram Malladi, University of Birmingham
A Phase II study of the use of azacitidine for the treatment of patients with chronic graft versus host disease who have failed therapy with corticosteroids
Amount awarded: £174,134
Award start date: 01 Mar 2015
Recruitment start date: 03 Jun 2016
Award duration: Award duration: 4 years (52 months)

Graft versus host disease (GvHD) may happen after a stem cell transplant (also known as a bone marrow transplant) from another person. GvHD is a condition in which the donor immune system (the “graft”) recognises the normal cells of the patient (the “host”) as “foreign” and attacks them leading to organ damage. People who have chronic GvHD are usually given steroids, which damp down the immune system. But this course of treatment does not always work as people can become dependent on steroids, or their steroid treatment may no longer work.

Researchers want to see if using a chemotherapy called azacitidine helps people with GvHD. Azacitidine’s exact mechanism of action is unknown, and it has more than one effect on cells. In GvHD, azacitidine is thought to modulate the immune system, allowing the graft cells to establish themselves.

The aim of the trial is to:

  • See if azacitidine is a useful treatment for people with GvHD 
  • See what the side effect are

You may be eligible to join this trial if:

  • You have moderate or severe chronic GvHD
  • You are dependent on steroids, are unable to have steroids or steroid treatment no longer works
  • You are aged 16 years or older